Humira

A new precision medicine test could help doctors and patients zero in on the right arthritis drug much sooner. But insurance coverage and drug company incentives are hurdles to widespread use.

Health & Safety

A new test could save arthritis patients time, money and pain. But will it be used?

7:01am December 20, 2023

by Arthur Allen

Stories of chronic pain, drug-hopping, and insurance meddling are all too common among patients with rheumatoid arthritis. Precision medicine offers new hope.

AbbVie's Humira was the world's best-selling drug for many years. Now it faces competition for copycats that cost a fraction of its price.

Health & Safety

Blockbuster drug Humira finally faces lower-cost rivals

9:57am July 20, 2023

by Sydney Lupkin

After years of being the world's best-selling drug, Humira faces competition from copycat versions known as biosimilars. One called Yusimry costs a $1,000 or less.

Queue Listen Now

Humira, the injectable biologic treatment for rheumatoid arthritis, now faces its first competition from one of several copycat "biosimilar" drugs expected to come to market this year. Some patients spend $70,000 a year on Humira.

Health & Safety

AbbVie's blockbuster drug Humira finally loses its 20-year, $200 billion monopoly

10:08am January 31, 2023

U.S. doctors can now choose Amjevita instead, the first of several close copies of the popular rheumatoid arthritis drug expected this year. But industry-watchers warn consumer savings may be limited.